Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

Clinical studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application of this combination has been limited by toxicities. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Xinghua, Huang, Zhaoliang, Zhong, Tingting, Zhang, Peng, Wang, Zhongmin Maxwell, Xia, Michelle, Li, Baiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012886/
https://www.ncbi.nlm.nih.gov/pubmed/36872527
http://dx.doi.org/10.1080/19420862.2023.2180794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012886/
https://www.ncbi.nlm.nih.gov/pubmed/36872527
http://dx.doi.org/10.1080/19420862.2023.2180794

Ejemplares similares